| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 天津红日药业股份有限公司是一家主要从事药品及医疗器械的生产经营和研究开发,公司主要产品包括血必净注射液、盐酸法舒地尔注射液及低分子量肝素钙注射液等药品.于2001年6月公司一次性全面通过GMP认证(证书编号C0943).公司是被评为天津市的高新技术企业,拥有专利8项(其中发明专利3项),已受理发明专利5项,申请科技部科研课题4项,国家发改委和天津市发改委科研课题1项、天津市科委科研课题7项.公司拥有国家新药证书8个,药品批准文号22个,全部剂型的生产车间均已通过GMP认证.公司的血必净注射液拥有2项国家发明专利;并获得"国家高技术产业发展投资计划"和"科技型中小企业创新基金项目"等多项支持,先后获得天津市2006年度技术创新优秀项目一等奖、中国中西医结合学会颁发的科学技术奖二等奖、天津市2007年度专利优秀奖及天津市2008年科技进步奖二等奖等奖项;2006年5月被科技部和国家保密局联合认定为"秘密级国家秘密技术",2009年被卫生部《甲型H1N1流感诊疗方案(2009年试行版第二版)》选定为中医辩证治疗药物.公司研发和产业化获得科技部"科技型中小企业创新基金"和天津市科委"科技成果转化项目成果认定项目"等多项支持。 | ||||||||||||||||||||||||
| Main Business | 中成药以及西药的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 吴文元 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 杨伊 | ||||||||||||||||||||||||
| Solicitors | 北京市康达律师事务所 | ||||||||||||||||||||||||
| Auditors | 瑞华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 022-59623217 | ||||||||||||||||||||||||
| Fax No | 022-59675226 | ||||||||||||||||||||||||
| Website | www.chasesun.cn | ||||||||||||||||||||||||
| yangyi@chasesun.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 30/10/2009 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.170 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.030 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 2.899 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 10.368B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |